PF1802

PF1802 is a bifunctional biological drug candidate being developed by ImmunoForge for the treatment of neurodegenerative diseases, specifically Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease. The molecule is a dual-ligand Fc fusion protein that utilizes ImmunoForge's proprietary Elastin-Like Polypeptide (ELP) platform technology. This platform is designed for half-life extension, allowing for less frequent dosing (potentially once-weekly or once-monthly). As a bifunctional molecule, PF1802 is engineered to engage two distinct ligands or targets simultaneously to address the complex pathology of neurodegeneration, although the specific identities of these targets are not publicly disclosed in the company's pipeline.